Navigation Links
Nastech Announces Third Quarter 2007 Financial Results
Date:10/29/2007

ion in restricted cash at each date. The increase in our cash balance was driven by the January 2007 offering of common stock which raised net proceeds of approximately $40.9 million.

Recent Corporate Highlights

* Initiated a Phase 2 clinical trial for PYY(3-36) Nasal Spray for

obesity

* Initiated a Phase 2 clinical trial for Insulin Nasal Spray for diabetes

* Announced promotion of Henry "Rick" Costantino to Chief Scientific

Officer of Delivery

Conference Call and Webcast Information

Management will host a conference call to review our financial results for the period ended September 30, 2007 and recent business developments. The call is scheduled for today, October 29, 2007, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). To participate in the live conference call, U.S. residents should dial (866) 831-6243 and international callers should dial (617) 213- 8855. The access code for the live conference call is 60453924. To access the 24-hour telephone replay, U.S. residents should dial (888) 286-8010 and international callers should dial (617) 801-6888. The access code for the replay is 53042322.

Alternatively, log on to http://www.nastech.com to access a live webcast or the subsequent archive. Please connect to the Investor section of Nastech's website several minutes prior to the start of the live conference call to ensure adequate time for any software download that may be necessary.

About Nastech

Nastech is a biopharmaceutical company developing innovative products based on proprietary molecular biology-based drug delivery technologies. Nastech and our collaboration partners are developing products for multiple therapeutic areas including osteoporosis, obesity, diabetes, autism, respiratory diseases and inflammatory conditions. Additional information about Nastech is available at http://ww
'/>"/>

SOURCE Nastech Pharmaceutical Company Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 30, 2015 ... reports results for the second quarter of 2015. ... group,s results and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics ... Q2 results - Performance drivers ...
(Date:7/29/2015)... , July 30, 2015 ... la santé, publie ses résultats pour le premier ... commente les résultats. Visionner l,interview ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de ... - Moteurs de croissance - ...
(Date:7/29/2015)... , July 30, 2015 According ... Market - Growth, Trends & Forecasts (2015-2020), , published by ... US$ 30.25 billion by the end of 2020, with ... accounting for more than 40% of the global market size. ... at a CAGR of 13.7% during the period of (2015-2020). ...
(Date:7/29/2015)... , July 29, 2015 US-Australian drug discovery ... today confirmed it is committed to progressing its ground-breaking ... as practicable and to ensure the Company delivers the ... Officer, Iain Ross , said the Company currently ... lead pre-clinical programs, discovery programs and academic partnerships and ...
Breaking Biology Technology:Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... to 26 in Kansas City. , ... Rockville, MD ... Annual Scientific Meeting (ASM) will be held in Kansas City, Mo., ... with the USP experts responsible for establishing internationally recognized standards for ...
... 3 ESA Biosciences, a Magellan,Biosciences company and ... for pharmaceutical development and QA/QC, life science, and,analytical-chemistry ... Frost & Sullivan North American Technology Innovation Award ... Sullivan will present the,award to ESA,s Vice President ...
... HOUSTON, Sept. 3 US Oncology Specialty, LP, ... the Occupational Excellence Achievement Award from the National,Safety ... award is presented to companies who produce the ... To be eligible, organizations must report,days away from ...
Cached Biology Technology: